For R/M HNSCC patients with PD-L1 expression ≥1% (HR = 0.76, 95% CI: 0.50–1.17), treatment with ICIs showed a PFS benefit compared to the control group; however, the difference was not statistically significant. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.